The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Over half of all individuals included in this study reported headache attacks occurring at specific time periods throughout the day.
The 2 treatments for cluster headache with Level A recommendations are either not readily accessible via public or private insurance or are not recommended in a large subset of patients with cardiovascular disease.
Despite a recent study concluding that oxygen therapy for cluster headache is not cost-prohibitive, many private payers and Medicare and Medicaid do not cover the effective therapy. Matthew Robbins, MD, Stewart Tepper, MD, and others weigh in on the controversial decision.
Painful signs and symptoms frequently occur prior to cluster headache attacks.
The current costs of medical grade oxygen for treating cluster headache are not "prohibitively expensive."
Patients can receive the gammaCore device by participating in the gammaCore Patient Registry program.
A follow-up study revealed the benefits of sphenopalatine ganglion stimulation for the prevention of cluster headache attacks.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
SPG stimulation is delivered on-demand through an implanted neurostimulator.
The therapy effects lasted for about a month, as researchers noted the procedure would need to be repeated for continuous relief.
The noninvasive device not only stopped acute attacks, but reduced overall headache frequency.
Neurology Advisor Articles
- Visual Association Test, MMSE Highly Predictive of Dementia in Older Adults
- Epilepsy's Mobility Problem: Advocating for Changes in Transportation Laws, Public Resources
- The Future of Freezing of Gait in Parkinson's: Exploring Potential Treatments and Preventive Strategies
- Women With Epilepsy More Likely to Have Major Depressive Disorder
- Some Common Allergies Linked to Odds of Autism in Children
- CAPPRI Scale is Feasible for Assessing Health-Related Quality of Life in Diabetic Distal Sensorimotor Polyneuropathy
- Long-Term Type 1 Diabetes Associated With Cognitive Decline
- White Matter Hyperintensities in RCVS Vary Over Time
- Disrupted Thalamo-Striato-Hypothalamic Function May Serve as a Good Biomarker for Parkinson Disease
- Levetiracetam Effective as Episodic Migraine Prophylactic